Evidence map›Paper›PMID 39987502›Full record

ArticleThe Medical journal of Australia2025

Management of Mycobacterium ulcerans infection (Buruli ulcer) in Australia: consensus statement.

Stephen Muhi, Victoria Rv Cox, Matthew O'Brien, Jonathan T Priestley, Jodie Hill, Adrian Murrie, Anthony McDonald, Peter Callan, Grant A Jenkin, N Deborah Friedman and 6 more

Abstract readConsensus Statement
In one paragraph

Article in The Medical journal of Australia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Buruli ulcer.Nature reviews. Disease primers · 2025
    Review
  6. Article
  7. Life (Basel, Switzerland) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Stephen MuhiPeter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC.
Victoria Rv CoxMenzies School of Health Research, Darwin, NT.
Matthew O'BrienMonash Children's Hospital, Melbourne, VIC.
Jonathan T PriestleySouth Coast Medical, Blairgowrie, VIC.
Jodie HillSouth Coast Medical, Blairgowrie, VIC.
Adrian MurrieSorrento Medical Centre, Sorrento, VIC.
Anthony McDonaldBarwon Health, Geelong, VIC.
Peter CallanBarwon Health, Geelong, VIC.
Grant A JenkinMonash Medical Centre, Melbourne, VIC.
N Deborah FriedmanPeter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC.
Kasha P SinghPeter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC.ORCID 0000-0002-5199-9331
Callum MaggsBarwon Health, Geelong, VIC.
Peter KelleyPeninsula Health, Melbourne, VIC.
Eugene AthanBarwon Health, Geelong, VIC.
Paul Dr JohnsonPeter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC.ORCID 0000-0001-9873-7163
Daniel P O'BrienVictorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, VIC.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionBuruli ulcer, caused by Mycobacterium ulcerans, is increasing in incidence and spreading to new areas in southeast Australia. With increasing experience and emerging evidence, this consensus statement considers contemporary data to provide up-to-date recommendations to clinicians who may encounter this disease. The emergence of Buruli ulcer in previously non-endemic areas highlights the importance of increasing clinician and community awareness of this disease. Main recommendations and changes in management as a result of this consensus statement: Buruli ulcer is a notifiable disease in Victoria, the Northern Territory and Queensland. Cases identified in other states or territories should be discussed with relevant health authorities. We call for Buruli ulcer to be made nationally notifiable to monitor for its potential emergence in non-endemic regions. Diagnosis using polymerase chain reaction is sensitive and specific if performed correctly; a dry swab under the undermined edge of ulcers or a tissue sample via punch biopsy if the lesion is not ulcerated is recommended. If swabs are incorrectly performed or performed on non-ulcerated skin, they can give a false negative result. There is high quality evidence to support treatment of eight weeks' duration using rifampicin-based dual oral antibiotic therapy, in combination with clarithromycin or a fluoroquinolone; relapse is very rare but can occur in people with risk factors. There is emerging evidence for shorter durations of treatment (six weeks) in individuals with small lesions who are at low risk of relapse and in those who have undergone surgical excision of the lesion (four weeks). Patients should be warned that ulcers typically enlarge with antibiotic treatment, will not have healed by completion of antibiotics, and take a median of four to five months to heal. Surgical management is usually not required, but may be beneficial to reduce healing times, avoid or reduce the duration of antibiotics, and manage paradoxical reactions. Early identification and treatment of paradoxical reactions is important, as they are associated with increased tissue necrosis and delayed wound healing. Good wound care is critical in successful treatment of Buruli ulcer, as it enhances healing and prevents secondary bacterial infection. Compared with adults, children have a higher proportion of non-ulcerative and severe lesions, are less likely to experience adverse antibiotic effects, but have higher rates of paradoxical reactions; specialist referral is recommended.

Indexed as

Anti-Bacterial AgentsBuruli UlcerMycobacterium ulceransAustraliaHumansRifampinAnti-Bacterial AgentsRifampinMycobacterium

Identifiers

PMID39987502
PMCPMC12167611

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.